Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reissued by HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $75.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential downside of 36.96% from the stock’s previous close.

A number of other analysts have also weighed in on SRPT. Evercore ISI cut their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Piper Sandler cut their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $178.71.

Sarepta Therapeutics Trading Down 0.4 %

SRPT opened at $118.97 on Thursday. The business has a fifty day moving average price of $123.41 and a 200 day moving average price of $131.36. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics has a 12 month low of $89.92 and a 12 month high of $173.25. The stock has a market capitalization of $11.36 billion, a price-to-earnings ratio of 95.18 and a beta of 0.77.

Insider Activity at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Garden State Investment Advisory Services LLC acquired a new stake in Sarepta Therapeutics in the third quarter valued at about $2,115,000. Tidal Investments LLC lifted its holdings in shares of Sarepta Therapeutics by 91.2% in the 3rd quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company’s stock valued at $704,000 after buying an additional 2,688 shares during the period. World Investment Advisors LLC purchased a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $2,418,000. Sunbelt Securities Inc. grew its holdings in Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 232 shares during the period. Finally, Geode Capital Management LLC raised its position in Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after acquiring an additional 44,306 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.